![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 7
2020
Multhoff, Gabriele; Seier, Sophie; Stangl, Stefan; Sievert, Wolfgang; Shevtsov, Maxim; Werner, Caroline; Pockley, A. Graham; Blankenstein, Christiane; Hildebrandt, Martin; Offner, Robert; Ahrens, Norbert; Kokowski, Konrad; Hautmann, Matthias; Roedel, Claus; Fietkau, Rainer; Lubgan, Dorota; Huber, Rudolf; Hautmann, Hubert; Duell, Thomas; Molls, Michael; Specht, Hanno; Haller, Bernhard; Devecka, Michal; Sauter, Andreas und Combs, Stephanie E.
(2020):
Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
In: Clinical Cancer Research, Bd. 26, Nr. 20: S. 5368-5379
2017
Camidge, D. Ross; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen; Hansen, Karin; Kim, Sang-We; Huber, Rudolf; West, Howard; Grön, Harry; Hochmair, Maximilian; Leighl, Natasha; Gettinger, Scott; Langer, Corey; Paz-Ares, Luis; Smit, Egbert; Kim, Edward; Reichmann, William; Clackson, Tim; Kerstein, David; Haluska, Frank und Kim, Dong-Wan
(2017):
Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial.
In: Journal of thoracic Oncology, Bd. 12, Nr. 1:
S1167-S1169
Gettinger, Scott; Kim, Dong-Wan; Tiseo, Marcello; Langer, Corey; Ahn, Myung-Ju; Shaw, Alice; Huber, Rudolf; Hochmair, Maximilian; Kim, Sang-We; Bazhenova, Lyudmila; Gold, Kathryn; Ou, Sai-Hong; West, Howard; Reichmann, William; Haney, Jeff; Clackson, Tim; Haluska, Frank; Kerstein, David und Camidge, D. Ross
(2017):
Brigatinib Activity in Patients with ALK plus NSCLC and Intracranial CNS Metastases in Two Clinical Trials.
In: Journal of thoracic Oncology, Bd. 12, Nr. 1:
S273-S274
Sequist, Lecia; Anderson, Ian; Atmaca, Akin; Bauer, Todd; Chae, Young; Cheng, Haiying; Cobo, Manuel; Demars, Nate; Felip, Enriqueta; Frost, Nikolaj; García Gómez, Ramón; Gray, Jhanelle; Harb, Wael; Horn, Leora; Huber, Rudolf; Isla, Dolores; Kudla, Arthur; Lee, Jean; Mathews, Sara; Mehra, Ranee; Modiano, Manuel; Nieva, Jorge; Rosales, Joseph; Shepherd, Frances; Spira, Alexander und Czibere, Akos
(2017):
Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC.
In: Journal of thoracic Oncology, Bd. 12, Nr. 1:
S1075-S1076
Tufman, Amanda; Reu, Simone; Hasmann, Sandra; Kauffmann-Guerrero, Diego; Milger, Katrin; Syunyaeva, Zulfiya; Kahnert, Kathrin und Huber, Rudolf
(2017):
Frequency and Clinical Relevance of EGFR-Mutations and EML4-ALK-Translocations in Octagenarians with NSCLC.
In: Journal of thoracic Oncology, Bd. 12, Nr. 1:
S686-S687
Tufman, Amanda; Siokou, Fiona; Müller-Lisse, Ullrich; Berger, Frank; Kahnert, Kathrin; Pfluger, Thomas; Reu, Simone; Stump, Julia; Winter, Hauke und Huber, Rudolf
(2017):
Clinical and Histological Features Associated with SUV in FDG-PET-CT in Patients with Adenocarcinoma of the Lung.
In: Journal of thoracic Oncology, Bd. 12, Nr. 1:
S558-S558
2016
Tian, Fei; Kiefl, Rosemarie; Tufman, Amanda und Huber, Rudolf
(2016):
The Hedgehog Pathway Inhibitor GDC-0449 Alters the Expression Level of the Pathway Components In Lung Cancer Cell Lines.
In: Chest, Bd. 149, Nr. 4:
299A-299A